Ziwig develops a saliva-based diagnostic test, Ziwig Endotest®, that utilizes RNA analysis and artificial intelligence to accurately identify endometriosis. This method addresses the need for a non-invasive, rapid diagnostic solution for women's health issues, providing reliable results within days.
Funding
Funding not disclosed
Founders
Product
Problem
Diagnosing endometriosis currently requires invasive surgical procedures, leading to delays in diagnosis and treatment for women experiencing symptoms. Existing diagnostic methods often lack the sensitivity and specificity needed for early and accurate detection of the disease.
Solution
Ziwig Endotest® is a saliva-based in-vitro diagnostic test that leverages RNA analysis and artificial intelligence to provide a non-invasive method for identifying endometriosis. The test analyzes salivary miRNA using next-generation sequencing (NGS) to identify phenotypic profiles characteristic of endometriosis, which are then modeled using AI. This approach offers a rapid and reliable diagnostic solution, delivering results within days from a simple saliva sample.
Target Audience
The primary users are healthcare professionals, specifically gynecologists and specialists in women's health, who require a reliable and non-invasive method for diagnosing endometriosis.
Features
- Saliva-based sample collection for non-invasive diagnosis
- RNA analysis using next-generation sequencing (NGS) technology
- AI-driven modeling of phenotypic profiles characteristic of endometriosis
- Rapid turnaround time, providing results in a few days
- High-throughput industrial capacity, analyzing up to 4500 samples per week
- CE certification as an in-vitro diagnostic medical device